Transdermal contraception methods: today’s patches and new options on the horizon

Bibliography

• Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15-44: United States, 2011-2013. NCHS Data Brief 2014(173):1-8
   PubMedGoogle Scholar
• Hatcher RA, Trussell J, Nelson AL et al. Contraceptive technology. 20th edition. Ardent Media; New York, NY: 2011. p. 50
   Google Scholar
• Nelson AL, Westhoff C, Schnare SM. Real-world patterns of prescription refills for branded hormonal contraceptives: a reflection of contraceptive discontinuation. Obstet Gynecol 2008;112(4):782-7
   PubMed Web of Science ®Google Scholar
• Potter L, Oakley D, de Leon-Wong E, Cañamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996;28(4):154-8
   PubMedGoogle Scholar
• Potts RO, Lobo RA. Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist. Obstet Gynecol 2005;105(5 Pt 1):953-61
   PubMedGoogle Scholar
• Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995;51(5):283-8
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179(3 Pt 1):577-82
   PubMed Web of Science ®Google Scholar
• Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000;65(10-11):629-36
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Small M, Kumar N, et al. Nestorone: clinical applications for contraception and HRT. Steroids 2003;68(10-13):907-13
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E, Kumar N, et al. An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive. Contraception 2007;76(6):432-8
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Nath A, Mishell DRJr. Contraception technology: past, present and future. Contraception 2013;87(3):319-30
   PubMed Web of Science ®Google Scholar
• Mahabadi V, Amory JK, Swerdloff RS, et al. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab 2009;94(7):2313-20
   PubMedGoogle Scholar
• Roth MY, Ilani N, Wang C, et al. Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels. Andrology 2013;1(6):899-905
   PubMedGoogle Scholar
• Roth MY, Shih G, Ilani N, et al. Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception 2014t;90(4):407-12
   PubMed Web of Science ®Google Scholar
• Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007;197(2):134.e1-6
   Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3-63
   PubMed Web of Science ®Google Scholar
• Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 2004;7(4):347-56
   PubMed Web of Science ®Google Scholar
• Jung-Hoffman C, Kuhl H. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism. Am J Obstet Gynecol 1990;163(6 Pt 2):2183-97
   PubMed Web of Science ®Google Scholar
• Munoz A. OESCLIM: an advanced delivery system for HRT. Maturitas 1999;33(Suppl 1):S39-47
   Google Scholar
• Sachdeva V, Bai Y, Kydonieus A, Banga AK. Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies. Int J Pharm 2013;441(1-2):9-18
   PubMedGoogle Scholar
• Scheindlin S. Transdermal drug delivery: PAST, PRESENT, FUTURE. Mol Interv 2004;4(6):308-12
   PubMed Web of Science ®Google Scholar
• Goldzieher JW, Brody SA. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol 1990;163(6 Pt 2):2114-19
   PubMed Web of Science ®Google Scholar
• Jain P, Banga AK. Induction and inhibition of crystallization in drug-in-adhesive-type transdermal patches. Pharm Res 2013;30(2):562-71
   PubMedGoogle Scholar
• Archer DF, Bigrigg A, Smallwood GH, et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002;77(2 Suppl 2):S27-31
   PubMed Web of Science ®Google Scholar
• Bitzer J, Gemzell-Danielsson K, Roumen F. The CHOICE study: effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reproduct Health Care 2012;17(1):65-78
   PubMed Web of Science ®Google Scholar
• Egarter C, Frey Tirri B, Bitzer J. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health 2013;13:9
   PubMed Web of Science ®Google Scholar
• Sidney S, Cheetham TC, Connell FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013;87(1):93-100
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006;73(3):223-8
   PubMed Web of Science ®Google Scholar
• Abrams LS, Skee D, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril 2002;77(2 Suppl 2):S3-12
   Web of Science ®Google Scholar
• Ortho Evra® (norelgestromin/ethinyl estradiol transdermal system) Product labeling. Ortho-McNeil Pharmaceuticals, Inc; Raritan, NJ: 2006
   Google Scholar
• Wooltorton E. The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns. CMAJ 2006;174(2):164-5
   PubMedGoogle Scholar
• de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014;3:CD010813
   PubMed Web of Science ®Google Scholar
• Heinemann LA, Dinger JC, Assmann A, Minh TD. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation “pill scare”. Contraception 2010;81(5):401-7
   PubMedGoogle Scholar
• Jensen JT, Burke AE, Barnhart KT, et al. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception 2008;78(6):451-8
   PubMed Web of Science ®Google Scholar
• Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005;105(5 Pt 1):1114-18
   PubMedGoogle Scholar
• Jick SS, Hagberg KW, Kaye JA. ORTHO EVRA and venous thromboembolism: an update. Contraception 2010;81(5):452-3
   PubMed Web of Science ®Google Scholar
• Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109(2 Pt 1):339-46
   PubMed Web of Science ®Google Scholar
• Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010;81(5):408-13
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in usersof non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012;344:e2990
   PubMed Web of Science ®Google Scholar
• Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010;81(1):16-21
   PubMed Web of Science ®Google Scholar
• Sidney S. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM2773.pdf
   Google Scholar
• Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005;143(10):697-706
   PubMed Web of Science ®Google Scholar
• Evra product label. Available from: https://www.ema.europa.eu/en_6B/document-librarg/EPAR_-_product-information/human/000410/wc500031512.pdf [ Last accessed 1 March 2015]
   Google Scholar
• WHO medical eligibility criteria for contraceptive use, fourth edition. Available from: http://www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/[ Last accessed 1 March 2015]
   Google Scholar
• US MEC, 2012. Available from: http://www.cdc.gov/reproductivehealth/unintendedpregnancy/usmec.htm [Last accessed 07 January 2015]
   Google Scholar
• Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002;77(2 Suppl 2):S13-18
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Gallo MF, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2008(1):CD003552
   Google Scholar
• Gallo MF, Nanda K, Grimes DA, et al. 20 µg versus > 20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2013;8:CD003989
   Google Scholar
• Urdl W, Apter D, Alperstein A, et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur J Obstet Gynecol Reprod Biol 2005;121(2):202-10
   PubMed Web of Science ®Google Scholar
• Jakimiuk AJ, Crosignani PG, Chernev T, et al. High levels of women’s satisfaction and compliance withtransdermal contraception: results from a European multinational, 6-month study. Gynecol Endocrinol 2011;27(10):849-56
   PubMed Web of Science ®Google Scholar
• Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001;285(18):2347-54
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2013;4:CD003552
   PubMedGoogle Scholar
• Creasy GW, Abrams LS, Fisher AC. Transdermal contraception. Semin Reprod Med 2001;19(4):373-80
   PubMedGoogle Scholar
• Abrams LS, Skee DM, Natarajan J, et al. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J Clin Pharmacol 2001;41(12):1301-9
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep. 2013.62(RR-05):1-60. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm [Last accessed 07 January 2015]
   Google Scholar
• Steinauer JE, Sokoloff A, Roberts EM, et al. Immediate versus delayed initiation of the contraceptive patch after abortion: a randomized trial. Contraception 2014;89(1):42-7
   PubMedGoogle Scholar
• Espey E, Ogburn T, Leeman L, et al. Effect of progestin compared with combined oral contraceptive pills on lactation: a randomized controlled trial. Obstet Gynecol 2012;119(1):5-13
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Portman D, Westhoff CL, et al. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial. Obstet Gynecol 2014;123(2 Pt 1):295-303
   PubMed Web of Science ®Google Scholar
• Foegh M, Archer DF, Stanczyk FZ, et al. Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel. Contraception 2013;87(2):201-11
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Archer DF, Rubin A, Foegh M. Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. Contraception 2013;87(6):744-9
   PubMed Web of Science ®Google Scholar
• Archer DF, Stanczyk FZ, Rubin A, Foegh M. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise. Contraception 2013;87(2):212-19
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Archer DF, Mishell DRJr, Foegh M. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women. Am J Obstet Gynecol 2014. [Epub ahead of print]
   Google Scholar
• Hofmann B, Reinecke I, Schuett B, et al. Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive. Int J Clin Pharmacol Ther 2014;52(12):1059-70
   PubMedGoogle Scholar
• Sibai BM, Odlind V, Meador ML, et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002;77(2 Suppl 2):S19-26
   Web of Science ®Google Scholar
• Höchel J, Schuett B, Ludwig M, Zurth C. Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study. Int J Clin Pharmacol Ther 2014;52(10):856-66
   PubMedGoogle Scholar
• Westhoff CL, Reinecke I, Bangerter K, Merz M. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles. Contraception 2014;90(3):272-9
   PubMedGoogle Scholar
• Merz M, Grunert J. Effects of an ethinyl estradiol/gestodene transdermal contraceptive patch on the endometrium: a single-center, uncontrolled study. Womens Health (Lond Engl) 2014;10(1):37-43
   PubMedGoogle Scholar
• Wiegratz I, Bassol S, Weisberg E, et al. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study. Reprod Sci 2014;21(12):1518-25
   PubMedGoogle Scholar
• Merz M, Kroll R, Lynen R, Bangerter K. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study. Contraception 2015;91(2):113-20
   PubMedGoogle Scholar
• Gruber D, Skřivánek A, Serrani M, et al. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study. Contraception 2015;91(2):105-12
   PubMedGoogle Scholar
• Jensen JT. The future of contraception: innovations in contraceptive agents: tomorrow’s hormonal contraceptive agents and their clinical implications. Am J Obstet Gynecol 2011;205(4 Suppl):S21-5
   Google Scholar
• Agrawal SS, Pruthi JK. Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. Contraception 2011;84(5):533-8
   PubMedGoogle Scholar
• Sachdeva V, Bai Y, Kydonieus A, Banga AK. Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies. Int J Pharm 2013;441(1-2):9-18
   PubMedGoogle Scholar
• Sucato GS, Land SR, Murray PJ, et al. Adolescents’ experiences using the contraceptive patch versus pills. J Pediatr Adolesc Gynecol 2011;24(4):197-203
   PubMedGoogle Scholar
• Stuart JE, Secura GM, Zhao Q, et al. Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users. Obstet Gynecol 2013;121(2 Pt 1):330-6
   PubMed Web of Science ®Google Scholar
• Martínez-Astorquiza-Ortiz de Zarate T, Díaz-Martín T, Martínez-Astorquiza-Corral T; MIA Study Investigators. Evaluation of factors associated with noncompliance in users of combined hormonal contraceptive methods: a cross-sectional study: results from the MIA study. BMC Womens Health 2013;13:38
   PubMed Web of Science ®Google Scholar
• Law A, Lee YC, Gorritz M, Plouffe L. Does switching contraceptive from oral to a patch or vaginal ring change the likelihood of timely prescription refill? Contraception 2014;90(2):188-94
   PubMedGoogle Scholar